Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

Carmen Escuriola Ettingshausen,Inga Hegemann,Mindy L. Simpson,Adam Cuker,Roshni Kulkarni,Rajiv K. Pruthi,May-Lill Garly,Rikke M. Meldgaard,Paula Persson,R. Klamroth

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial

2019

Carmen Escuriola Ettingshausen
Inga Hegemann
Mindy L. Simpson
Adam Cuker
Roshni Kulkarni
Rajiv K. Pruthi
May-Lill Garly
Rikke M. Meldgaard
Paula Persson
R. Klamroth

Background and Objective Nonacog beta pegol (N9‐GP) and recombinant factor IX‐Fc fusion protein (rFIXFc) are extended half‐life rFIX compounds. We report the first single‐dose pharmacokinetic trial of N9‐GP and rFIXFc.

Keywords:

Factor IX
Randomized controlled trial
Crossover study
Recombinant factor IX
Fusion protein
Beta (finance)
Pharmacology
Pharmacokinetics
Medicine
Clinical trial
Clinical endpoint
Protein A

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations